Novo: The Double Bottom Is In

Novo Nordisk ( NVO ) delivered a mixed Q3, and the stock continues to hover near all-time lows. But beneath the noise, the long-term story continues to be compelling, with strength in obesity drugs and a good pipeline of upcoming products.James Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth. Th ...